Mekinist Europeiska unionen - svenska - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanom - antineoplastiska medel - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 och 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. icke-småcellig lungcancer (nsclc)trametinib i kombination med dabrafenib är indicerat för behandling av vuxna patienter med avancerad icke-småcellig lungcancer med braf v600-mutation.